Ophthalmic Research

Download Fulltext PDF

Review Article

Free Access

The Role of Steroids in the Management of Diabetic Macular Edema

Zur D.a · Iglicki M.b · Loewenstein A.a

Author affiliations

aDivision of Ophthalmology, Tel Aviv Sourasky Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
bPrivate Retina Service, University of Buenos Aires, Buenos Aires, Argentina

Corresponding Author

Dinah Zur, MD

Division of Ophthalmology, Tel Aviv Sourasky Medical Center

Weizman 6

Tel Aviv 64239 (Israel)

E-Mail dinahzur@gmail.com

Keywords: SteroidsDiabetic macular edemaTreatmentCurrent algorithm

Related Articles for ""
Ophthalmic Res 2019;62:231–236
https://doi.org/10.1159/000499540

Abstract

Inflammation is substantially contributing to the development and worsening of diabetic retinopathy in general and diabetic macular edema (DME) in particular, which provides the rationale to treat DME with corticosteroids. While anti-vascular endothelial growth factor (VEGF) agents are mostly chosen as a first-line treatment, there is an important role for steroids in the treatment algorithm for DME. A slow-release bioerodible dexamethasone implant and an extended-release nonbioerodible fluocinolone acetonide insert are both approved for the treatment of DME and provide the advantage of sustained drug delivery and reduced treatment burden. Steroids bare the complications of cataract progression and increase of intraocular pressure (IOP). However, with dexamethasone implant, IOP rise is well manageable with topical treatment in almost all cases. Dexamethasone implant has been shown to be effective in the treatment of naive DME as well as in eyes nonresponding to anti-VEGF agents. In these cases, early switching to steroids may be considered and has been shown to be beneficial. Fluocinolone acetonide is reserved for severe cases of chronic DME insufficiently responsive to other available therapies. Future randomized controlled trials are needed to realize the role of steroids in the current treatment algorithm of DME.

© 2019 S. Karger AG, Basel

Diabetic Retinopathy – An Inflammatory Disease?

While glycemic control and systemic blood pressure are important in the prevention of diabetic microvascular complications, these do no solely account for their development [1, 2]. Inflammation has been shown to play a major role in the pathogenesis of atherothrombosis and microalbuminuria in diabetic patients [3, 4]. Lately, there is growing evidence that inflammation is important in the development and worsening of diabetic retinopathy in general [5, 6] and diabetic macular edema (DME) in particular [7-9]. Low-grade subclinical inflammation, specifically adherent leukocytes, are responsible for the development of vascular pathologies in diabetic retinopathy. Leukostasis in retinal capillaries is an early event in the cascade of DME, causing dysfunction of the blood-retinal barrier (BRB) [10]. In an experimental setting, diabetes caused adherence and accumulation of leucocytes within the retinal vasculature and a subsequent migration of leucocytes into the neural retina [11-13]. These early microscopic changes precede any clinical signs of diabetic retinopathy.

The expression of proinflammatory cytokines, such as intracellular adhesion molecule (ICAM)-1 [14], interleukin-6 (IL-6), tumor necrosis factor (TNF), and cyclooxygenase-2, is upregulated [8], further neutrophils and monocytes are attracted, and vascular permeability deteriorates.

Experiments in diabetic rats showed that treatments with ICAM-1- or β2 integrin-neutralizing antibodies were able to suppress leucocyte adhesion, stabilize the BRB, and even prevent endothelial cell injury and its apoptosis [15-17]. Moreover, the inhibition of leucocyte adhesion via ICAM-1 and CD18 showed long-term suppression of diabetic complications [18].

A large-scale prospective clinical study combined systemic C-reactive protein, IL-6, and TNF-α levels in an inflammatory marker Z-score, which was found to be significantly associated with retinopathy and other systemic microvascular complications of diabetes mellitus [19].

Vascular endothelial growth factor (VEFG) has a central implication in the pathogenesis of DME. Being mainly a vasogenic factor, VEGF also has the power to trigger inflammation by inducing ICAM-1 expression, leucocyte adhesion, and monocyte migration [20-22]. In experimental settings, intravitreous injections of VEGF induced leukostasis in the retina, enhancing vascular permeability and capillary nonperfusion [20]. Leukostasis itself was accompanied by upregulation of retinal ICAM-1 expression. When bioactivity of this molecule was inhibited by a neutralizing antibody, permeability and leukostasis were strongly inhibited.

The Rationale for Use of Steroids in the Treatment of DME

Corticosteroids provide powerful anti-inflammatory and anti-edematous effects by targeting not only the synthesis of proinflammatory mediators involved in DME (IL-6, IL-8, MCP-1, ICAM-1, TNF-α, VEGF, HGF, ANGPT2, etc.) [23] but also a decrease in VEGF synthesis. Corticosteroids block the arachidonic acid pathway via phospholipase A2 inhibition and, hence, downregulate the synthesis of thromboxanes, leukotrienes, and prostaglandins. Consequently, the BRB improves, density and activity of tight junctions in the retinal capillary endothelium enhance, and retinal oxygenation ameliorates.

Müller cells are essential to maintain the homeostasis in the retina. There is growing evidence suggesting that Müller cells may be the first to be affected in DME, showing intracellular edema. Activated Müller cells release cytotoxic substances which are responsible for the recruitment of leukocytes, BRB breakdown, direct glial dysfunction, and neuronal cell death. With progression of the disease, they may become apoptotic [24]. Gliotic Müller cells not only promote but also inhibit tissue repair processes in preclinical studies [25]. The rational approach for treating DME with corticosteroids involves targeting those inflammatory processes and preventing changes in the retinal glia.

Corticosteroid Agents

This paper will discuss 3 of the most commonly used corticosteroid agents: triamcinolone acetonide (TA), dexamethasone (DEX) implant, and fluocinolone acetonide (FA) implant.

Triamcinolone Acetonide

Prospective clinical trials have shown its efficacy in the treatment of DME [26-28]. The DRCR.net reported the use of intravitreal TA for DME in protocol I evaluating 3 different treatment schemes: intravitreal 0.5 mg ranibizumab plus prompt or deferred focal/grid laser; or 4 mg intravitreal TA combined with focal/grid laser compared with focal/grid laser alone [29]. Pseudophakic patients treated with TA faired similarly to the ranibizumab-treated group in terms of visual outcome and anatomical results after 2 years of follow-up. The mean elimination half-life of TA in the vitreous of a nonvitrectomized eye was 18.6 days, in contrast to a much shorter duration in a vitrectomized eye, 3.2 days [30]. As every drug that does not have a reservoir and does not work as a long-lasting drug, TA needs to be given as repeated injections, which raises the risk for complications, i.e., cataract formation and glaucoma. Uncontrolled increased intraocular pressure (IOP) might lead to glaucoma surgeries. That is why 2 sustained-release drugs (DEX implant and FA devices) were developed.

DEX Implant

DEX is a potent anti-inflammatory agent; its potency is twice that of FA and 5-fold more than that of TA [23]. Due to its high water solubility, DEX needs to be delivered in a sustained-release system to provide vitreous drug levels over time.

DEX implant (Ozurdex®; Allergan Inc., Irvine, CA, USA) is commercially available as a sterile, preloaded single-use applicator. It is inserted into the vitreous cavity with a 22-G needle via the pars plana and contains 0.7 mg of DEX. The biodegradable implant contains polylactic acid-co-glycolic acid polymers which degrade into carbon dioxide and water after slow release of DEX. Pharmacokinetic studies of DEX implant showed an initially high rate of DEX release over the first 2 months after injection, followed by a decrease in release until 6 months [31]. Intravitreal administration of DEX implant provides a high initial drug concentration with a maximum at 60 days, followed by a prolonged period of low concentration, similar to drug levels achieved with pulse corticosteroid treatment. In contrast to TA, the pharmacokinetics of the DEX implant were not significantly different in vitrectomized and nonvitrectomized animal eyes [32]. This can be explained by the fact that DEX implant does not require the vitreous as a substrate to work due to its own environment, i.e., the slow-release device.

The efficacy and safety of DEX implant has been shown in two 3-year multicenter, randomized, masked, sham injection-controlled phase III clinical trials (MEAD study) [33]. Minimum treatment intervals between repeated DEX implants were 6 months, and patients received on average 4–5 treatments over the study period. A larger portion of patients treated with DEX implant achieved a significant improvement in best corrected visual acuity (BCVA) (22.4 vs. 12.0%, p < 0.002) and a statistically significant reduction in central macular thickness (112 vs. 42 μm, p < 0.001) compared to patients in the sham group. The registration trial for Ozurdex® (MEAD), included mainly phakic patients (75%) with long-standing DME (mean duration 23 months) who were previously treated by macular laser photocoagulation in 65.8%, other corticosteroids in 16.5%, or anti-VEGF injections in 7.1%. Only 25% of the patients were treatment naive. In phakic eyes, mean BCVA improvement was substantial until the time of report of cataract, and improvement in vision from baseline was restored after cataract surgery. Furthermore, DEX implant is the only drug which was prospectively investigated in a group of vitrectomized eyes with DME: the CHAMPLAIN study showed an improvement of 6 and 3 letters at 8 and 26 weeks, respectively, after a single DEX implant. At 8 weeks, 30.4% of patients gained ≥10 letters [34].

In a recent multicenter, open-label, 12-month, randomized, parallel-group study, DEX implant met the a priori criterion for noninferiority to ranibizumab in improvement of BCVA over 12 months [35]. Both DEX implant and ranibizumab were well tolerated and improved BCVA in patients with DME. Noninferiority was achieved with an average of 2.9 DEX implant injections and 8.7 ranibizumab injections per patient with a more significant reduction in central macular thickness using DEX implant (122 vs. 187 μm, p = 0.015).

Similarly, the 24-month results of the BEVORDEX study identified no significant difference in the proportion of eyes with a 10-letter gain in VA between bevacizumab and DEX implant treatment, with both agents providing good improvements [36]. The burden of injections was significantly greater with bevacizumab (mean 9.1 vs. 2.8).

As treatment frequency may be set at shorter intervals than in the MEAD trial, real-life studies are of great importance in case of DEX implant. Several large-scale studies have been showing the efficacy with improvement in BCVA and decrease in retinal thickness [37-39], even in eyes with DME refractory to anti-VEGF [38, 40-42]. There was a trend to use DEX implant in DME eyes not responding to anti-VEGF treatments. Several papers have shown not only the benefits of using DEX implant in naive DME as a first-line option [38, 43], but also the advantages of early switching in patients not responding to anti-VEGF [42].

Protocol U by the DRCR.net aimed to compare continued ranibizumab injections alone with ranibizumab plus DEX implant in eyes with persistent DME [44]. This phase 2 randomized clinical trial included eyes after at least 3 anti-VEGF injections before a run-in phase, which included additional 3-monthly ranibizumab injections before receiving the study drug. The authors concluded that the combination therapy with DEX implant caused a greater reduction in retinal thickness; the addition of DEX implant did not improve visual acuity at 24 weeks more than continued ranibizumab therapy alone. However, the study design has some limitations which might have biased the outcome. There was no definition of “persistence of DME”: edema could have been improved significantly but still be defined as persistent. For eligibility, monthly treatment was not mandatory, and patients might have been undertreated before inclusion. Moreover, it should be noted that there was a subgroup of patients with baseline BCVA <20/50 who experienced a greater gain in vision with combination therapy compared to continued ranibizumab injections (+6.2 vs. +3.3 letters). As there were only 27 patients in each group, the difference did not reach statistical significance.

The main side effects of DEX implant are cataract development and IOP increase. In the MEAD trial, 27.7% of patients treated with 0.7-mg DEX implant experienced an increase of ≥10 mm Hg; in 6.6% IOP reached ≥35 mm Hg. While 41.5% needed IOP-lowering medications, only 2 patients treated with DEX implant underwent incisional surgery. Data from real-life studies show an increase of IOP in 10–17% of patients, well managed with topical treatment [38, 43].

FA Implant

FA is commercially available as a sustained-release system in a 25-G inserter, lasting up to 36 months in the vitreous. In contrast to DEX implant, FA implant has not the potential to be bioerodible. The Fluocinolone Acetonide for Diabetic Macular Edema (FAME) studies evaluated the use of 2 different FA doses (0.2 vs. 0.5 μg/day) compared to sham injections. A total of 953 DME eyes were randomized 1:2:2 [45, 46]. At 36 months, a significantly higher percentage of patients in both FA groups gained 15 or more letters in vision compared to patients in the sham group (p = 0.018). In contrast to TA and DEX implant, the incidence of side effects was higher after FA treatment. Almost all phakic patients in the FA groups developed cataract over 36 months. However, visual outcome after cataract surgery was comparable to pseudophakic patients. Furthermore, the development of uncontrolled IOP after TA was higher, and the incidence of incisional glaucoma surgery at month 36 was 4.8% in the low-dose group and 8.1% in the high-dose insert group. The FDA approved ILUVIEN® (FA intravitreal implant) 0.19 mg for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in IOP. The results from the FAME trial have been confirmed by real-life studies [47-49].

Diabetic Retinopathy Modification

The pathogenesis of diabetic retinopathy development and progression is complex and multifactorial. Vitreous VEGF levels have been shown to correlate with disease severity to be associated with diabetic retinopathy progression [50]. While the efficacy of anti-VEGF treatment in modifying diabetic retinopathy disease progression is well established [51-54], the role of corticosteroids has been less explored. However, the potential effect of intravitreal steroids can be well explained by the contribution of proinflammatory cytokines and chemokines to the disease development and retinal ischemia [5, 55, 56].

An exploratory analysis of the protocol I by the DRCR.net revealed that intravitreal TA has the potential to reduce the risk of diabetic retinopathy progression [57, 58]. Querques et al. [59] showed a reduction in peripheral retinal ischemia in DME eyes after treatment with intravitreal DEX after a short follow-up of 12 weeks. Lately, the authors of this review published the DRProDEX study which provides long-term evidence that DEX implant not only delays progression of diabetic retinopathy and proliferative diabetic retinopathy development, but also improves diabetic retinopathy severity over 24 months [60]. A post hoc analysis of the FAME trials showed delay in progression of proliferative diabetic retinopathy after treatment with FA intravitreal implant for DME [61].

Recommendations

Anti-VEGF agents are widely used as a first-line option for DME, but it has been proven that DEX implant can be used for patients with naive DME and not only for refractory cases. In cases not responding to monthly anti-VEGF injections, switching to DEX implant should be done early in order to allow optimal treatment outcomes [62]. Furthermore, there are special populations in which corticosteroids should be chosen as first-line therapy:

  • Patients who have a recent history of a cardiovascular event

  • Pregnancy

  • Inability or not willing to adhere to monthly treatments

  • DME in eyes undergoing cataract surgery.

In patients proven to be nonsteroid responders suffering from chronic DME that is not responsive to other treatments, FA can be given. TA should be used only in cases who do not have the possibility to receive the approved agents, as it needs to be reinjected frequently and causes more increase in IOP and cataract.

In conclusion, intravitreal corticosteroids provide substantial anatomical and functional improvement with sustained release in both naive and refractory DME. Further prospective studies are needed to determine their role in the treatment algorithm of DME. A well-designed head-to-head prospective trial is needed to determine the optimal treatment in this customized era.

Disclosure Statement

The authors declare no conflict of interest.


Related Articles:

References

  1. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int. 2001 Jul;60(1):219–27.
    External Resources
  2. Chaturvedi N, Sjoelie AK, Porta M, Aldington SJ, Fuller JH, Songini M, et al.; EURODIAB Prospective Complications Study. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care. 2001 Feb;24(2):284–9.
    External Resources
  3. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000 Mar;342(12):836–43.
    External Resources
  4. Schalkwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Dräger AM, et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia. 1999 Mar;42(3):351–7.
    External Resources
  5. Funatsu H, Yamashita H, Noma H, Mimura T, Nakamura S, Sakata K, et al. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol. 2005 Jan;243(1):3–8.
    External Resources
  6. Zhou J, Wang S, Xia X. Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Curr Eye Res. 2012 May;37(5):416–20.
    External Resources
  7. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol. 2002 Apr;86(4):363–5.
    External Resources
  8. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009 Jan;116(1):73–9.
    External Resources
  9. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 2008 Apr;30(2):65–84.
    External Resources
  10. Leal EC, Manivannan A, Hosoya K, Terasaki T, Cunha-Vaz J, Ambrósio AF, et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2007 Nov;48(11):5257–65.
    External Resources
  11. Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA. 1999 Sep;96(19):10836–41.
    External Resources
  12. Barouch FC, Miyamoto K, Allport JR, Fujita K, Bursell SE, Aiello LP, et al. Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci. 2000 Apr;41(5):1153–8.
    External Resources
  13. Schröder S, Palinski W, Schmid-Schönbein GW. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol. 1991 Jul;139(1):81–100.
    External Resources
  14. McLeod DS, Lefer DJ, Merges C, Lutty GA. Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am J Pathol. 1995 Sep;147(3):642–53.
    External Resources
  15. Miyamoto K, Hiroshiba N, Tsujikawa A, Ogura Y. In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci. 1998 Oct;39(11):2190–4.
    External Resources
  16. Xu Q, Qaum T, Adamis AP. Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci. 2001 Mar;42(3):789–94.
    External Resources
  17. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol. 2001 Jan;158(1):147–52.
    External Resources
  18. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004 Sep;18(12):1450–2.
    External Resources
  19. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD; EURODIAB Prospective Complications Study Group. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes—the EURODIAB Prospective Complications Study. Diabetologia. 2005 Feb;48(2):370–8.
    External Resources
  20. Miyamoto K, Khosrof S, Bursell SE, Moromizato Y, Aiello LP, Ogura Y, et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol. 2000 May;156(5):1733–9.
    External Resources
  21. Lu M, Perez VL, Ma N, Miyamoto K, Peng HB, Liao JK, et al. VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci. 1999 Jul;40(8):1808–12.
    External Resources
  22. Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med. 1990 Dec;172(6):1535–45.
    External Resources
  23. Whitcup SM, Cidlowski JA, Csaky KG, Ambati J. Pharmacology of corticosteroids for diabetic macular edema. Invest Ophthalmol Vis Sci. 2018 Jan;59(1):1–12.
    External Resources
  24. Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R. Diabetic Macular Edema Pathophysiology: vasogenic versus Inflammatory. J Diabetes Res. 2016;2016:2156273.
    External Resources
  25. Bringmann A, Iandiev I, Pannicke T, Wurm A, Hollborn M, Wiedemann P, et al. Cellular signaling and factors involved in Müller cell gliosis: neuroprotective and detrimental effects. Prog Retin Eye Res. 2009 Nov;28(6):423–51.
    External Resources
  26. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002 May;109(5):920–7.
    External Resources
  27. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 2004 Feb;111(2):218–24.
    External Resources
  28. Audren F, Lecleire-Collet A, Erginay A, Haouchine B, Benosman R, Bergmann JF, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol. 2006 Nov;142(5):794–9.
    External Resources
  29. Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM, et al.; Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011 Apr;118(4):609–14.
    External Resources
  30. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB 3rd, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003 Apr;110(4):681–6.
    External Resources
  31. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011 Jan;52(1):80–6.
    External Resources
  32. Chang-Lin JE, Burke JA, Peng Q, Lin T, Orilla WC, Ghosn CR, et al. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci. 2011 Jun;52(7):4605–9.
    External Resources
  33. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, et al.; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014 Oct;121(10):1904–14.
    External Resources
  34. Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, et al.; Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011 May;31(5):915–23.
    External Resources
  35. Callanan DG, Loewenstein A, Patel SS, Massin P, Corcóstegui B, Li XY, et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2017 Mar;255(3):463–73.
    External Resources
  36. Fraser-Bell S, Lim LL, Campain A, Mehta H, Aroney C, Bryant J, et al. Bevacizumab or Dexamethasone Implants for DME: 2-year Results (The BEVORDEX Study). Ophthalmology. 2016 Jun;123(6):1399–401.
    External Resources
  37. Guigou S, Pommier S, Meyer F, Hajjar C, Merite PY, Parrat E, et al. Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema. Ophthalmologica. 2015;233(3-4):169–75.
    External Resources
  38. Iglicki M, Busch C, Zur D, Okada M, Mariussi M, Chhablani JK, et al. Dexamethasone implant for diabetic macular edema in naive compared with refractory eyes: The International Retina Group Real-Life 24-Month Multicenter Study. The IRGREL-DEX Study. Retina. 2019 Jan;39(1):44–51.
    External Resources
  39. Zur D, Iglicki M, Busch C, Invernizzi A, Mariussi M, Loewenstein A, et al. OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant. Ophthalmology. 2018 Feb;125(2):267–275.
    External Resources
  40. Alshahrani ST, Dolz-Marco R, Gallego-Pinazo R, Diaz-Llopis M, Arevalo JF; KKESH International Collaborative Retina Study Group. Intravitreal dexamethasone implant for the treatment of refractory macular edema in retinal vascular diseases: Results of the KKESH International Collaborative Retina Study Group. Retina. 2016 Jan;36(1):131–6.
    External Resources
  41. Pacella F, Romano MR, Turchetti P, Tarquini G, Carnovale A, Mollicone A, et al. An eighteen-month follow-up study on the effects of Intravitreal Dexamethasone Implant in diabetic macular edema refractory to anti-VEGF therapy. Int J Ophthalmol. 2016 Oct;9(10):1427–32.
    External Resources
  42. Busch C, Zur D, Fraser-Bell S, Laíns I, Santos AR, Lupidi M, et al.; International Retina Group. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetol. 2018 Aug;55(8):789–96.
    External Resources
  43. Malclès A, Dot C, Voirin N, Agard É, Vié AL, Bellocq D, et al. Real-life study in diabetic macular edema treated with dexamethasone implant: The Reldex Study. Retina. 2017 Apr;37(4):753–60.
    External Resources
  44. Maturi RK, Glassman AR, Liu D, Beck RW, Bhavsar AR, Bressler NM, et al.; Diabetic Retinopathy Clinical Research Network. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. 2018 Jan;136(1):29–38.
    External Resources
  45. Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, et al.; FAME Study Group. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011 Apr;118(4):626–635.e2.
    External Resources
  46. Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, et al.; FAME Study Group. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012 Oct;119(10):2125–32.
    External Resources
  47. Eaton A, Koh SS, Jimenez J, Riemann CD. The USER Study: A Chart Review of Patients Receiving a 0.2 μg/day Fluocinolone Acetonide Implant for Diabetic Macular Edema. Ophthalmol Ther. 2019 Mar;8(1):51–62.
    External Resources
  48. Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J, Bailey C, et al.; Medisoft Audit Group. Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Eye (Lond). 2017 Dec;31(12):1707–15.
    External Resources
  49. Chakravarthy U, Taylor SR, Koch FH, Castro de Sousa JP, Bailey C. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. Br J Ophthalmol. 2018 Sep. doi: 10.1136/bjophthalmol-2018-312284.
    External Resources
  50. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994 Dec;331(22):1480–7.
    External Resources
  51. Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al.; RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013 Oct;120(10):2013–22.
    External Resources
  52. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al.; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012 Apr;119(4):789–801.
    External Resources
  53. Ip MS, Zhang J, Ehrlich JS. The Clinical Importance of Changes in Diabetic Retinopathy Severity Score. Ophthalmology. 2017 May;124(5):596–603.
    External Resources
  54. Bressler SB, Liu D, Glassman AR, Blodi BA, Castellarin AA, Jampol LM, et al.; Diabetic Retinopathy Clinical Research Network. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. JAMA Ophthalmol. 2017 Jun;135(6):558–68.
    External Resources
  55. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009 Sep;94(9):3171–82.
    External Resources
  56. dell’Omo R, Semeraro F, Bamonte G, Cifariello F, Romano MR, Costagliola C. Vitreous mediators in retinal hypoxic diseases. Mediators Inflamm. 2013;2013:935301.
    External Resources
  57. Bressler NM, Edwards AR, Beck RW, Flaxel CJ, Glassman AR, Ip MS, et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol. 2009 Dec;127(12):1566–71.
    External Resources
  58. Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, et al.; Diabetic Retinopathy Clinical Research Network. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol. 2013 Aug;131(8):1033–40.
    External Resources
  59. Querques L, Parravano M, Sacconi R, Rabiolo A, Bandello F, Querques G. Ischemic index changes in diabetic retinopathy after intravitreal dexamethasone implant using ultra-widefield fluorescein angiography: a pilot study. Acta Diabetol. 2017 Aug;54(8):769–73.
    External Resources
  60. Iglicki M, Zur D, Busch C, Okada M, Loewenstein A. Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the ‘DR-Pro-DEX Study’. Acta Diabetol. 2018 Jun;55(6):541–7.
    External Resources
  61. Wykoff CC, Chakravarthy U, Campochiaro PA, Bailey C, Green K, Cunha-Vaz J. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy. Ophthalmology. 2017 Apr;124(4):440–9.
    External Resources
  62. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222.
    External Resources

Author Contacts

Dinah Zur, MD

Division of Ophthalmology, Tel Aviv Sourasky Medical Center

Weizman 6

Tel Aviv 64239 (Israel)

E-Mail dinahzur@gmail.com

Article / Publication Details

First-Page Preview
Abstract of Review Article

Received: March 03, 2019
Accepted: March 09, 2019
Published online: May 02, 2019
Issue release date: November 2019

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0

ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)

For additional information: https://www.karger.com/ORE

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int. 2001 Jul;60(1):219–27.
    External Resources
  2. Chaturvedi N, Sjoelie AK, Porta M, Aldington SJ, Fuller JH, Songini M, et al.; EURODIAB Prospective Complications Study. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care. 2001 Feb;24(2):284–9.
    External Resources
  3. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000 Mar;342(12):836–43.
    External Resources
  4. Schalkwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Dräger AM, et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia. 1999 Mar;42(3):351–7.
    External Resources
  5. Funatsu H, Yamashita H, Noma H, Mimura T, Nakamura S, Sakata K, et al. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol. 2005 Jan;243(1):3–8.
    External Resources
  6. Zhou J, Wang S, Xia X. Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Curr Eye Res. 2012 May;37(5):416–20.
    External Resources
  7. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol. 2002 Apr;86(4):363–5.
    External Resources
  8. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009 Jan;116(1):73–9.
    External Resources
  9. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 2008 Apr;30(2):65–84.
    External Resources
  10. Leal EC, Manivannan A, Hosoya K, Terasaki T, Cunha-Vaz J, Ambrósio AF, et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2007 Nov;48(11):5257–65.
    External Resources
  11. Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA. 1999 Sep;96(19):10836–41.
    External Resources
  12. Barouch FC, Miyamoto K, Allport JR, Fujita K, Bursell SE, Aiello LP, et al. Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci. 2000 Apr;41(5):1153–8.
    External Resources
  13. Schröder S, Palinski W, Schmid-Schönbein GW. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol. 1991 Jul;139(1):81–100.
    External Resources
  14. McLeod DS, Lefer DJ, Merges C, Lutty GA. Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am J Pathol. 1995 Sep;147(3):642–53.
    External Resources
  15. Miyamoto K, Hiroshiba N, Tsujikawa A, Ogura Y. In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci. 1998 Oct;39(11):2190–4.
    External Resources
  16. Xu Q, Qaum T, Adamis AP. Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci. 2001 Mar;42(3):789–94.
    External Resources
  17. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol. 2001 Jan;158(1):147–52.
    External Resources
  18. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004 Sep;18(12):1450–2.
    External Resources
  19. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD; EURODIAB Prospective Complications Study Group. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes—the EURODIAB Prospective Complications Study. Diabetologia. 2005 Feb;48(2):370–8.
    External Resources
  20. Miyamoto K, Khosrof S, Bursell SE, Moromizato Y, Aiello LP, Ogura Y, et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol. 2000 May;156(5):1733–9.
    External Resources
  21. Lu M, Perez VL, Ma N, Miyamoto K, Peng HB, Liao JK, et al. VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci. 1999 Jul;40(8):1808–12.
    External Resources
  22. Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med. 1990 Dec;172(6):1535–45.
    External Resources
  23. Whitcup SM, Cidlowski JA, Csaky KG, Ambati J. Pharmacology of corticosteroids for diabetic macular edema. Invest Ophthalmol Vis Sci. 2018 Jan;59(1):1–12.
    External Resources
  24. Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R. Diabetic Macular Edema Pathophysiology: vasogenic versus Inflammatory. J Diabetes Res. 2016;2016:2156273.
    External Resources
  25. Bringmann A, Iandiev I, Pannicke T, Wurm A, Hollborn M, Wiedemann P, et al. Cellular signaling and factors involved in Müller cell gliosis: neuroprotective and detrimental effects. Prog Retin Eye Res. 2009 Nov;28(6):423–51.
    External Resources
  26. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002 May;109(5):920–7.
    External Resources
  27. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 2004 Feb;111(2):218–24.
    External Resources
  28. Audren F, Lecleire-Collet A, Erginay A, Haouchine B, Benosman R, Bergmann JF, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol. 2006 Nov;142(5):794–9.
    External Resources
  29. Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM, et al.; Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011 Apr;118(4):609–14.
    External Resources
  30. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB 3rd, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003 Apr;110(4):681–6.
    External Resources
  31. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011 Jan;52(1):80–6.
    External Resources
  32. Chang-Lin JE, Burke JA, Peng Q, Lin T, Orilla WC, Ghosn CR, et al. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci. 2011 Jun;52(7):4605–9.
    External Resources
  33. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, et al.; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014 Oct;121(10):1904–14.
    External Resources
  34. Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, et al.; Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011 May;31(5):915–23.
    External Resources
  35. Callanan DG, Loewenstein A, Patel SS, Massin P, Corcóstegui B, Li XY, et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2017 Mar;255(3):463–73.
    External Resources
  36. Fraser-Bell S, Lim LL, Campain A, Mehta H, Aroney C, Bryant J, et al. Bevacizumab or Dexamethasone Implants for DME: 2-year Results (The BEVORDEX Study). Ophthalmology. 2016 Jun;123(6):1399–401.
    External Resources
  37. Guigou S, Pommier S, Meyer F, Hajjar C, Merite PY, Parrat E, et al. Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema. Ophthalmologica. 2015;233(3-4):169–75.
    External Resources
  38. Iglicki M, Busch C, Zur D, Okada M, Mariussi M, Chhablani JK, et al. Dexamethasone implant for diabetic macular edema in naive compared with refractory eyes: The International Retina Group Real-Life 24-Month Multicenter Study. The IRGREL-DEX Study. Retina. 2019 Jan;39(1):44–51.
    External Resources
  39. Zur D, Iglicki M, Busch C, Invernizzi A, Mariussi M, Loewenstein A, et al. OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant. Ophthalmology. 2018 Feb;125(2):267–275.
    External Resources
  40. Alshahrani ST, Dolz-Marco R, Gallego-Pinazo R, Diaz-Llopis M, Arevalo JF; KKESH International Collaborative Retina Study Group. Intravitreal dexamethasone implant for the treatment of refractory macular edema in retinal vascular diseases: Results of the KKESH International Collaborative Retina Study Group. Retina. 2016 Jan;36(1):131–6.
    External Resources
  41. Pacella F, Romano MR, Turchetti P, Tarquini G, Carnovale A, Mollicone A, et al. An eighteen-month follow-up study on the effects of Intravitreal Dexamethasone Implant in diabetic macular edema refractory to anti-VEGF therapy. Int J Ophthalmol. 2016 Oct;9(10):1427–32.
    External Resources
  42. Busch C, Zur D, Fraser-Bell S, Laíns I, Santos AR, Lupidi M, et al.; International Retina Group. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetol. 2018 Aug;55(8):789–96.
    External Resources
  43. Malclès A, Dot C, Voirin N, Agard É, Vié AL, Bellocq D, et al. Real-life study in diabetic macular edema treated with dexamethasone implant: The Reldex Study. Retina. 2017 Apr;37(4):753–60.
    External Resources
  44. Maturi RK, Glassman AR, Liu D, Beck RW, Bhavsar AR, Bressler NM, et al.; Diabetic Retinopathy Clinical Research Network. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. 2018 Jan;136(1):29–38.
    External Resources
  45. Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, et al.; FAME Study Group. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011 Apr;118(4):626–635.e2.
    External Resources
  46. Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, et al.; FAME Study Group. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012 Oct;119(10):2125–32.
    External Resources
  47. Eaton A, Koh SS, Jimenez J, Riemann CD. The USER Study: A Chart Review of Patients Receiving a 0.2 μg/day Fluocinolone Acetonide Implant for Diabetic Macular Edema. Ophthalmol Ther. 2019 Mar;8(1):51–62.
    External Resources
  48. Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J, Bailey C, et al.; Medisoft Audit Group. Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Eye (Lond). 2017 Dec;31(12):1707–15.
    External Resources
  49. Chakravarthy U, Taylor SR, Koch FH, Castro de Sousa JP, Bailey C. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. Br J Ophthalmol. 2018 Sep. doi: 10.1136/bjophthalmol-2018-312284.
    External Resources
  50. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994 Dec;331(22):1480–7.
    External Resources
  51. Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al.; RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013 Oct;120(10):2013–22.
    External Resources
  52. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al.; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012 Apr;119(4):789–801.
    External Resources
  53. Ip MS, Zhang J, Ehrlich JS. The Clinical Importance of Changes in Diabetic Retinopathy Severity Score. Ophthalmology. 2017 May;124(5):596–603.
    External Resources
  54. Bressler SB, Liu D, Glassman AR, Blodi BA, Castellarin AA, Jampol LM, et al.; Diabetic Retinopathy Clinical Research Network. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. JAMA Ophthalmol. 2017 Jun;135(6):558–68.
    External Resources
  55. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009 Sep;94(9):3171–82.
    External Resources
  56. dell’Omo R, Semeraro F, Bamonte G, Cifariello F, Romano MR, Costagliola C. Vitreous mediators in retinal hypoxic diseases. Mediators Inflamm. 2013;2013:935301.
    External Resources
  57. Bressler NM, Edwards AR, Beck RW, Flaxel CJ, Glassman AR, Ip MS, et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol. 2009 Dec;127(12):1566–71.
    External Resources
  58. Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, et al.; Diabetic Retinopathy Clinical Research Network. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol. 2013 Aug;131(8):1033–40.
    External Resources
  59. Querques L, Parravano M, Sacconi R, Rabiolo A, Bandello F, Querques G. Ischemic index changes in diabetic retinopathy after intravitreal dexamethasone implant using ultra-widefield fluorescein angiography: a pilot study. Acta Diabetol. 2017 Aug;54(8):769–73.
    External Resources
  60. Iglicki M, Zur D, Busch C, Okada M, Loewenstein A. Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the ‘DR-Pro-DEX Study’. Acta Diabetol. 2018 Jun;55(6):541–7.
    External Resources
  61. Wykoff CC, Chakravarthy U, Campochiaro PA, Bailey C, Green K, Cunha-Vaz J. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy. Ophthalmology. 2017 Apr;124(4):440–9.
    External Resources
  62. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222.
    External Resources

Article Tools
Article Details

2019, Vol.62, No. 4

November 2019

Article

Recommend This
Open Access Gateway
Additional Information

Anat Loewenstein is the incumbent of the Sydney A. Fox Chair in Ophthalmology, Tel Aviv University, Tel Aviv, Israel.

TOP